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5 DMT provokes dramatic modifications in perception, the sense of self and reality that can be very intense but relatively short in duration . The drug also exerts marked autonomic effects elevating blood pressure, heart rate and rectal temperature, and causes mydriasis . Unlike the vast majority of known psychedelic phenethylamines, tryptamines and ergolines, DMT is orally inactive (Ott, 1999) , apparently due to metabolism by monoamine oxidase (MAO; Suzuki et al., 1981) . Interestingly, harmine and harmaline, and to a lesser extent THH, are potent MAO inhibitors (Buckholtz and Boggan, 1977; McKenna et al., 1984) .
In 1968 Agurell and coworkers (cited in Ott, 1999) postulated that the interaction between β-carbolines and DMT in ayahuasca "might result in specific pharmacological effects". It is now a widely accepted hypothesis that following ayahuasca ingestion, MAO-inhibition brought about by harmine, given that it is more potent than THH and is present in the tea in larger amounts than harmaline (McKenna et al., 1984) , prevents the enzymatic degradation of DMT allowing its absorption. It has also been speculated that β-carbolines may contribute to the overall central effects of ayahuasca by blocking brain MAO and weakly inhibiting serotonin reuptake, which combined would lead to enhanced neurotransmitter levels and modulate the effects of DMT (Callaway et al., 1999) .
In the present paper we report a double-blind placebo-controlled crossover clinical trial conducted with ayahuasca, in which subjective and cardiovascular effects, and alkaloid pharmacokinetics were assessed in a group of healthy volunteers experienced in psychedelic drug use. Additionally, urine monoamine metabolites were studied in order to measure in vivo the MAO-inhibitory effects of ayahuasca. In this respect, the neurotransmitters norepinephrine, epinephrine and dopamine are physiologically degraded by MAO and cathecol-O-mehtyltransferase (COMT) to This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on June 5, 2017 jpet.aspetjournals.org Downloaded from JPET #49882 6 produce deaminated and methylated metabolites, respectively. Serotonin, on the other other hand, is exclusively metabolized by MAO to produce a deaminated compound. In vivo and in vitro studies have shown that when MAO is pharmacologically inhibited the levels of MAO-dependent deaminated metabolites decrease and those of COMTdependent mehtylated metabolites increase. In humans, MAO inhibitors decrease, after acute administration, the urinary excretion of vanilmandelic acid (VMA), homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA), the deaminated metabolites of norepinephrine/epinephrine, dopamine and serotonin, respectively; while increasing that of metanephrine and normetanephrine, the methylated metabolites of epinephrine and norepinephrine, respectively (Koulu et al., 1989; Pletscher, 1966) . Monoamine metabolites have both a CNS and a non-CNS origin and their assessment in urine does not give information regarding the organ where MAO was inhibited. Nevertheless, this approach can identify dose-response relationships after drug administration and allows for the study of the time course of MAO-inhibition.
This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods

Volunteers
A total of eighteen volunteers (fifteen males and three females) with experience in psychedelic drug use were recruited by word of mouth. Eligibility criteria required prior use of psychedelics on at least five occasions without sequelae derived thereof, i.e., psychedelic-related disorders as described in the DSM-III-R. Participants had used psychedelics from six to hundreds of times. The most commonly used psychedelic was LSD (17/18) followed by psilocybian mushrooms (15/18) and ketamine (10/18). The least commonly used were peyote (3/18), Salvia divinorum (3/18), mescaline (2/18), Amanita muscaria (2/18) and Datura stramonium (1/18). Although prior exposure to ayahuasca was not required for participation, two of the volunteers had ingested this tea before inclusion. Besides psychedelics, volunteers had consumed cannabis (18/18), cocaine (17/18) and MDMA (17/18). Volunteers were in good health, confirmed by medical history, laboratory tests, ECG and urinalysis. Prior to physical examination, volunteers were interviewed by a psychiatrist (structured interview for DSM-III-R) and completed the trait-anxiety scale from the State-Trait Anxiety Inventory (Spielberger et al., 1970) . Exclusion criteria included current or previous history of psychiatric disorder and/or family history of Axis-I psychiatric disorder in first degree relatives, alcohol or other substance dependence, and high scores on trait anxiety (over 1 standard deviation above normative mean). Participants had a mean age of 25.7 years (range: 19-38), mean weight 66.47 kg (range: 50.7-79.5) and mean height 175.11 cm (range 158-188). The All volunteers gave their written informed consent to participate.
Drug
In order to administer ayahuasca in accurate dosings and masked in a doubleblind, double-dummy design, a 9.6 liter batch of Brazilian Daime was subjected to a freeze-drying process that yielded 611 grams of powder, which was subsequently homogenized and analyzed. The DMT content was determined by HPLC, as described by Callaway and coworkers (1996) , and the β-carbolines according to a modified version of the method described therein. One gram of freeze-dried material contained 8.33 mg DMT, 14.13 mg harmine, 0.96 mg harmaline and 11.36 mg THH, which corresponded to the following alkaloid concentrations in the original tea: DMT 0.53 mg/ml, harmine 0.90 mg/ml, harmaline 0.06 mg/ml and THH 0.72 mg/ml. The ayahuasca doses administered to the volunteers in the present study were chosen based on tolerability and subjective effect data gathered in a previous study (Riba et al., 2001a) . The low and the high dose contained per kg body weight: 0.6/0.85 mg DMT, DMT administered with the present low dose was similar to that administered in the only other published study on the human pharmacology of ayahuasca (Callaway et al., 1999) , the amounts of β-carbolines administered in this work were much lower. This was due to the different alkaloid proportions present in the tea samples used in each study. Thus, the average amounts (range) in mg administered by .2) for DMT, for harmine, 29.7(24.0-36.0) for harmaline, and 158. 8(128.4-196.6 ) for THH.
Study design
Each volunteer participated in four experimental sessions at least 1 week apart.
Volunteers were informed that on each experimental day they would randomly receive a single oral dose of encapsulated freeze-dried ayahuasca (one low and one high dose), a placebo and a random repetition of one of the three mentioned treatments. In actual fact, they all received a placebo on the first experimental day in a single-blind fashion, followed by one of the three treatments from days two to four in a double-blind balanced fashion, according to a randomization table. The first non-randomized placebo was administered in order to familiarize the volunteers with the experimental setting and to minimize the stress associated with the experimental interventions. Volunteers were requested to abstain from any medication or illicit drug use two weeks prior to the beginning of the experimental sessions until the completion of the study. Volunteers also abstained from alcohol, tobacco and caffeinated drinks 24 h prior to each experimental day. Urinalysis for illicit drug use was performed for each experimental session. The volunteers were admitted to the research unit on four separate experimental days. Upon arrival at 8:00 am under fasting conditions, a cannula was inserted in the cubital vein of their right arm for drawing blood samples, and capsules were This article has not been copyedited and formatted. The final version may differ from this version. 
Study Methods
Subjective effect measures
The subjective effects elicited by ayahuasca were measured by means of visual analogue scales (VAS) and self-report questionnaires. VAS were 100-mm horizontal lines with the following labels: "any effect" indicating any effect, either physical or psychological that the volunteer attributed to the administered drug; "good effects" indicating any effect the volunteer valued as good; "liking" reflecting that the volunteer liked the effects of the administered substance; "drunken" indicating any dizziness or lightheadedness; "stimulated" indicating any increases in thought speed and/or content, or any increases in associations and/or insights; "visions" indicating modifications in visual perception, including any variations in object shape, brightness or color and any illusion, abstract or elaborate, seen with either eyes closed or open; and "high" which reflected any positive psychological effect the volunteer attributed to the drug. Except for the "visions" item, the other VAS items administered had been used in human studies by other researchers assessing the subjective effects of a variety of psychoactive drugs Farré et al., 1993; Farré et al., 1998) . The volunteers were requested to answer the VAS immediately before administration (baseline) and at 15, 30, 45, 60, 75 min, and 1.5, 2, 2.5, 3, 3.5, 4, 6 and 8 hours after administration. Self-report questionnaires included the Hallucinogen Rating Scale (HRS) and the Addiction Research Center Inventory (ARCI). The HRS measures psychedelic-induced subjective effects and includes six scales: Somaesthesia, reflecting somatic effects; Affect, sensitive to emotional and affective responses; Volition, indicating the volunteer's capacity to willfully interact with his/her "self" and/or the environment; Cognition, describing modifications in thought processes or content; Perception, measuring visual, auditory, gustatory and olfactory experiences; and finally Intensity, which reflects the strength of the overall experience. In the present study, a Spanish adaptation of the questionnaire was used (Riba et al., 2001b) . The range of scores for all HRS scales is 0 to 4. The short version of the ARCI (Martin et al., 1971 ) consists of five scales or groups: MBG, morphine-benzedrine group, measuring euphoria and positive mood; PCAG, pentobarbital-chlorpromazine-alcohol group, measuring sedation; LSD, lysergic acid diethylamide scale, measuring somaticdysphoric effects; BG, the benzedrine group, measuring intellectual energy and efficiency, and the A scale, an empirically derived scale measuring amphetamine-like effects. Both the A and BG scales are sensitive to psychostimulants. The range of scores is 0 to 16 for MBG, -4 to 11 for PCAG, -4 to 10 for LSD, -4 to 9 for BG, and 0 to 11 for A. The questionnaire had been translated into Spanish and validated by Lamas and coworkers (1994) . Volunteers answered the ARCI immediately before drug administration, and four hours after drug intake, whereas the HRS was only answered at four hours post-administration. The following monoamine metabolites: VMA, HVA, 5-HIAA, metanephrine, and normetanephrine were quantified by means of HPLC with coulometric detection following previously validated procedures (Gamache et al., 1993; Parker et al., 1986; Soldin and Hill, 1980) (Yritia et al., 2002) . The limit of quantification was 1.6 ng/ml for DMT, 0.5 ng/ml for harmine, 0.3 ng/ml for harmaline, 1.0 ng/ml for THH, and 0.3 ng/ml for harmol and harmalol. The intra-day and inter-day coefficients of variation were lower than 10.9% and 13.4%, respectively, for all determined compounds.
Pharmacokinetic analysis
After quantification of the different compounds in plasma, the following pharmacokinetic parameters were calculated using a non-compartmental approach by All data are expressed as mean ± SD except for T max where median and range are given.
Statistics
Prior to statistical analysis ARCI scores were transformed to differences from pre-administration values, and the following parameters were calculated for VAS items: peak effect (maximum absolute change from baseline values), time taken to reach the maximum effect (t max ), and the 8-hour area under the curve (AUC 0-8h ) of effect versus This article has not been copyedited and formatted. The final version may differ from this version. Monoamine metabolite levels in urine were analyzed by means of a one-way repeated measures ANOVA with drug (placebo, ayahuasca low dose, ayahuasca high dose) as factor. When a significant effect was observed, post-hoc comparisons were performed using Tukey's test. The time course of effects was explored using repeated measures two-way ANOVAs with drug and time (3 time points) as factors.
Pharmacokinetic parameter comparisons between doses were performed by means of Student's t-test, except for T max , which was compared by means of a nonparametric Wilcoxon test.
In order to explore possible differences in the time-to-peak of DMT plasma concentrations and time-to-peak of subjective effects (for each of the administered VAS), non-parametric Wilcoxon tests were performed comparing T max for DMT and t max for each VAS. These tests were performed for data obtained after each of the two administered ayahuasca doses.
In all tests performed, differences were considered statistically significant for p values lower than 0.05. 
Results
Subjective effects
Subjective effects results are shown in Tables 1 and 2 and Figures 1 and 2. --------------------------Insert Table 1 about here
Ayahuasca administration induced significant increases in all six HRS scales, both after the low and the high dose, except for Volition, which showed statistically significant differences from placebo only after the 0.85 mg DMT/kg dose. The ARCI questionnaire showed statistically significant dose-dependent increases after ayahuasca in measures of stimulatory effects (A scale), euphoria (MBG scale) and somatic symptoms (LSD scale). Scores on the BG and PCAG scales were not significantly different from placebo.
Scorings on all seven VAS items showed significant drug effects (peak values and AUC) and significant drug by time interactions. Initial effects appeared between 30 and 45 min, reflected as rises in the VAS any effect item, and were followed by a prominent increase at around 60 min, as indicated by steep rises in all seven VAS items.
In general terms the maximum scorings were observed between 90 and 120 min after drug administration. A gradual return to baseline levels followed thereafter and was complete at 360 min. Regarding effect magnitude, the largest scores were obtained for the VAS any effect, liking and high, followed by VAS good effects, visions and stimulated items. The least modified VAS after ayahuasca administration was the drunken item.
A more qualitative information on the nature of the effects brought about by ayahuasca is provided in Table 2 , which lists the most frequently reported positive responses to specific items of the HRS questionnaire. Table 2 here
Cardiovascular effects
Mean values for systolic (SBP) and diastolic blood pressure (DBP) and heart rate (HR) over time are presented in Figure 3 and results of the statistical analysis performed are shown in Table 1 . Figure 3 here JPET #49882 18 significant effect of drug only for normetanephrine. No significant drug by time interaction was found for any of the metabolites studied. In view of this, the total monoamine metabolite amounts excreted during the 0-24 h period after placebo and the two ayahuasca doses are presented in Table 3 . As shown therein, rather than the expected decreases in deaminated metabolites (VMA, HVA, 5-HIAA), drug administration increased the excretion of these compounds non-significantly. Similarly, levels of the O-methylated metabolites metanephrine and normetanephrine increased with dose, although only the latter showed statistically significant differences with placebo.
--------------------------
Insert Table 3 here
Pharmacokinetics
The time course of plasma concentrations and the calculated pharmacokinetic parameters for DMT, harmaline, THH, harmol and harmalol are shown in Figure 4 and Table 4 . The graphs correspond to 15 of the total 18 participants enrolled in the study.
In order to avoid the miscalculation of pharmacokinetic parameters, data from three volunteers were excluded from the analysis due to vomiting occurring after administration of the low dose (volunteer 6) and the high dose (volunteers 4 and 18).
An additional subject (volunteer 12) was excluded from the calculation of harmalol parameters. Plasma levels for this volunteer after the high dose showed a plateau between 6 and 24 h precluding parameter assessment. 
--------------------------Insert Figure 4 here ----------------------------------------------------
Insert Table 4 here
As shown in Table 4 , C max and AUC values increased with dose for all measured compounds. DMT showed a T max of 1.5 h (median) after both the low and high doses.
Nevertheless, the upper end of the range of T max values increased with dose and the
Wilcoxon test indicated a statistically significant difference between doses. A larger
T max after the high ayahuasca dose is evident also in the DMT concentration-time curve included in Figure 4 . Both harmaline and THH plasma concentrations peaked later than DMT and their T max values were larger after the high relative to the low ayahuasca dose.
An unexpected finding was the absence of measurable harmine plasma levels except for a few time points in four out of 18 volunteers, precluding the calculation of pharmacokinetic parameters for this alkaloid.
Interestingly, all volunteers showed measurable levels of harmol, the Odemethylated analogue of harmine. Plasma concentrations showed dose-dependent increases and peaked at 1.5 and 2 h after the low and high doses, respectively.
Harmalol, the O-demethylated analogue of harmaline could also be quantified.
Maximum concentrations were attained later than for harmaline, with T max observed at 2.5 and 2.75 h after the low and high dose, respectively. The AUC normalized by dose was calculated for each parent alkaloid and these values compared between doses by means of a paired Student's t test. A statistically significant difference was found for DMT suggesting, a possible non-proportional increase of plasma levels between doses. In line with this possibility, mean V z /F and Cl/F values calculated for DMT decreased with dose. These decreases were statistically significant for V z /F and showed a tendency for Cl/F (t(14)=1.94, p= 0.073).
In support of a parallel evolution of DMT plasma levels and subjective effects, no significant differences were found between DMT T max values and any of the seven VAS t max values at any of the two administered ayahuasca doses.
This article has not been copyedited and formatted. The final version may differ from this version. Increases in VAS-high have been observed after a great variety of drugs including MDMA , cocaine (Farré et al., 1993) and the sedative flunitrazepam (Farré et al., 1998) . The VAS-stimulated item reflects more specifically the effects of psychostimulants such as amphetamine and MDMA . Increases in VAS-drunken, which was the least modified VAS item by ayahuasca, have been observed mainly after sedatives such as flunitrazepam (Farré et al., 1998) , and alcohol (Farré et al., 1993) , but also after 125 mg MDMA . Regarding the HRS, our findings are in line with results by other researchers who have demonstrated statistically significant increases in all HRS scales after the administration of various psychedelics, such as intravenous (IV) DMT and oral psilocybin Gouzoulis-Mayfrank et al., 1999) . However, ayahuasca differed from these drugs in the time course of effects. The overall duration was longer than that of IV DMT, but shorter than that of mescaline or LSD (Strassman, 1994) . Finally, regarding the ARCI questionnaire, increases in the ARCI-A, ARCI-BG and ARCI-MBG scales are a common feature of psychostimulants (Lamas et al., 1994; Martin et al., 1971) .
However, in contrast with drugs like amphetamine, methamphetamine, ephedrine and methylphenidate (Martin et al., 1971) , ayahuasca did not induce significant increases in (Brawley and Duffield, 1972 ).
The present results on the subjective effects induced by ayahuasca in a clinical research setting replicate those obtained in a preliminary study involving a smaller sample of volunteers with prior experience with ayahuasca, and with a single-blind non-randomized design (Riba et al., 2001a) . In the mentioned study, statistically significant increases were observed in all HRS items, except volition, and in the ARCI-MBG, ARCI-LSD and ARCI-A scales. In the present study, however, scores on these measures at the 0.6 and 0.85 mg DMT/kg doses tended to be lower than those obtained after 0.5 and 0.75 mg DMT/kg doses, respectively. Several factors such as sample size, study design and prior exposure to ayahuasca could account for these differences.
Scores on the HRS items at the present low dose were also lower than those reported by Grob and coworkers (1996) , except for the somaesthesia and perception items, after the administration of an equivalent ayahuasca dose -in terms of DMT content-to a group of experienced long-term ritual users. Nevertheless, scores on all HRS items after the present high dose were higher than those reported by these researchers. Compared with IV DMT as described by , ayahuasca evokes effects of milder intensity which show a slower onset and a longer overall duration. Scorings on the six HRS scales after the present high dose fell between those reported after 0.1 and 0.2 mg/kg IV DMT.
In our previous study on ayahuasca (Riba et al., 2001a) we failed to observe statistically significant modifications of cardiovascular parameters in a five-subject sample. In the present work, only modifications in DBP reached statistical significance. (Mas et al., 1999; de la Torre et al., 2000) . DBP increases from baseline values after both ayahuasca doses were somewhat lower than the elevations from baseline values reported by Callaway and coworkers (1999) after an ayahuasca dose containing 0.48 mg DMT/kg but larger amounts of β-carbolines.
The time course of DMT plasma concentrations closely paralleled that of subjective effects. The steep rise in DMT plasma levels observed at 1 h coincided with an analogous rise in VAS scores, and peak DMT concentrations and peak effects were obtained between 1.5 and 2 h. In the present study, quantifiable plasma levels were observed for DMT and THH. T max values for DMT and THH were similar to those reported by Callaway et al. (1999) . However, C max values for DMT and THH in the present study were lower than expected, even after taking into account the smaller amounts administered in the case of THH. This could be due to a lower alkaloid bioavailability from the lyophilizate compared to the aqueous solution administered by Callaway and coworkers. The calculated V z /F values are similar in both studies but Callaway and coworkers reported higher t 1/2 and lower Cl/F values. In the case of DMT these differences may be associated with the lower levels of harmala alkaloids present in our ayahuasca and the consequent lower degree of MAO inhibition. In addition to these inter-study differences, it is interesting to note that the normalized AUC calculated for DMT in the present study showed a statistically significant increase between the low and the high ayahuasca doses. This is suggestive of a non-linear increment of DMT levels following the administration of increasing doses of ayahuasca. Considering that both V z /F and Cl/F decreased in a similar proportion between doses, these data could be interpreted as indicating a greater DMT bioavailability following the high dose, This article has not been copyedited and formatted. The final version may differ from this version. Another relevant difference with the study by Callaway and coworkers (1999) is the lack of measurable concentrations of harmine in plasma and the presence of significant levels of harmol and harmalol. Differences in ayahuasca harmine content alone cannot entirely explain the absence of this alkaloid in plasma, considering that THH was present in the lyophilizate in similar amounts to those of harmine and was later measurable in plasma. Thus, harmine was either not absorbed in the gastrointestinal tract or was extensively degraded by first-pass metabolism before reaching systemic circulation. The presence of harmol in plasma would support the second hypothesis. Harmol glucuronide and harmol sulfate have been described as the main urine metabolites of harmine following its IV administration in humans (Slotkin et al., 1970) . A very recent study has found cytochrome P450 to catalyze the Odemethylation of harmine and harmaline, and has identified CYP2D6 and CYP1A1 as the major isoenzymes involved in the process (Yu et al., 2003) . Nevertheless, we cannot conclude that harmine was completely metabolized to render harmol as very small amounts of harmol and harmalol have been detected in B.caapi and ayahuasca (Rivier and Lindgren, 1972; McKenna et al., 1984) . Thus, it cannot be entirely ruled out that at least part of the amounts found in plasma could have been ingested with the tea.
The low plasma levels found for harmine in the present study could explain the absence of a clear-cut MAO-inhibitor effect on the urinary excretion of monoamine metabolites. The acute administration of a MAO-A inhibitor induces a decrease in the levels of oxidized deaminated monoamine metabolites and an increase in the levels of COMT-dependent methylated compounds (Koulu et al., 1989; Pletscher, 1966) . While in the present study normetanephrine, a methylated breakdown product of norepinephrine, showed statistically significant increases after dosing with ayahuasca, the levels of the deaminated metabolites measured, i.e., VMA, HVA and 5-HIAA, did not show decreases, but were rather non-significantly increased. It is thus unclear whether the observed neurotransmitter metabolite profile was secondary to MAO inhibition. An alternative explanation would be an increase in norepinephrine release induced by DMT, which would fit well the observed sympathomimetic properties of this compound. However, this assumption is not supported by the limited available evidence from related compounds. Results obtained in two studies involving LSD administration to humans found no drug effects on monoamine metabolite excretion (Hollister and Moore, 1967; Messiha and Grof, 1973) and to our knowledge no data are available on the effects of parentheral DMT on these measures. In any case, MAO inhibition by ayahuasca alkaloids effectively facilitated the access of DMT to systemic circulation but may have been insufficiently potent or insufficiently prolonged to modify the profile of deaminated metabolites in the 8 h urine collection periods used.
To conclude, the present findings indicate that following ayahuasca administration to humans measurable DMT plasma levels are obtained together with distinct psychedelic effects. Psychoactivity is attained with negligible levels of circulating harmine. These results and the lack of a clear-cut systemic MAO-inhibitor effect are suggestive of a harmine-DMT interaction predominantly taking place in the gastrointestinal tract and possibly in the liver. Harmine effects at a peripheral level would appear to suffice to prevent first-pass metabolism of DMT and allow its access to the CNS in amounts able to evoke psychotropic effects. 
